Maxcyte Inc (MXCT)

$0.78 -0.06 (-6.65%)
Market Cap 89.14M
Revenue (ttm) 38.63M
Net Income (ttm) -41.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -106.29%
Debt to Equity Ratio 0.00
Volume 1,087,300
Avg Vol 1,115,818
Day's Range N/A - N/A
Shares Out 106.67M
Stochastic %K 33%
Beta 1.22
Analysts Strong Sell
Price Target $7.00

Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications;...

Industry: Medical Devices
Sector: Healthcare
Phone: 301 944 1700
Address:
9713 Key West Avenue, Suite 400, Rockville, United States
Mindegap
Mindegap Mar. 6 at 7:57 PM
$MXCT My understanding is that $PRME works with their tech and they are planning to file a BLA for their ex vivo CGD following final FDA alignment. If approved will be the first prime editing drug on the market. DYODD, not financial advice.
1 · Reply
BeefStewart
BeefStewart Mar. 5 at 9:19 PM
$MXCT not bad today. 🙏
0 · Reply
BeefStewart
BeefStewart Mar. 5 at 5:42 PM
$MXCT 🙏🩵
0 · Reply
Mindegap
Mindegap Mar. 5 at 4:41 PM
$MXCT Interesting and odd... But no complaints!
1 · Reply
Playtheplayers
Playtheplayers Mar. 4 at 4:58 PM
$MXCT I sold glta
0 · Reply
BeefStewart
BeefStewart Mar. 2 at 9:01 PM
$MXCT what a day.
0 · Reply
BeefStewart
BeefStewart Mar. 2 at 8:04 PM
$CRSP $MXCT seems to be showing signs of life too!
0 · Reply
BeefStewart
BeefStewart Mar. 2 at 1:01 PM
$MXCT $QURE and $CLPT dropping... $NTLA up... Wondering if/how MaxCyte will react to these premarket updates...
0 · Reply
BeefStewart
BeefStewart Feb. 27 at 9:28 PM
$MXCT Not bad.
0 · Reply
CH_Expat
CH_Expat Feb. 27 at 5:12 PM
$MXCT Only 35% down.
1 · Reply
Latest News on MXCT
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

Feb 24, 2026, 8:05 AM EST - 10 days ago

MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

Feb 23, 2026, 4:05 PM EST - 11 days ago

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

Jan 12, 2026, 8:05 AM EST - 7 weeks ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

Dec 1, 2025, 9:00 AM EST - 3 months ago

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:11 PM EST - 4 months ago

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

MaxCyte Announces Planned CFO Transition in 2026

Nov 12, 2025, 4:08 PM EST - 4 months ago

MaxCyte Announces Planned CFO Transition in 2026

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Nov 12, 2025, 4:05 PM EST - 4 months ago

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Nov 5, 2025, 8:05 AM EST - 4 months ago

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 8, 2025, 8:05 AM EDT - 5 months ago

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

Oct 6, 2025, 8:05 AM EDT - 5 months ago

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Sep 22, 2025, 4:30 PM EDT - 5 months ago

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 3:45 AM EDT - 7 months ago

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

MaxCyte Signs Platform License Agreement with Adicet Bio

Aug 4, 2025, 8:05 AM EDT - 7 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

Jul 31, 2025, 8:05 AM EDT - 7 months ago

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 9, 2025, 8:05 AM EDT - 8 months ago

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan

Jul 1, 2025, 1:00 AM EDT - 8 months ago

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

Jun 11, 2025, 2:00 AM EDT - 9 months ago

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript

May 10, 2025, 11:57 PM EDT - 10 months ago

MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

May 7, 2025, 4:05 PM EDT - 10 months ago

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 10, 2025, 2:00 AM EDT - 11 months ago

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

Mar 15, 2025, 8:30 AM EDT - 1 year ago

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:52 PM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

Mar 11, 2025, 4:05 PM EDT - 1 year ago

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

Feb 12, 2025, 2:00 AM EST - 1 year ago

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Feb 7, 2025, 2:00 AM EST - 1 year ago

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

Jan 30, 2025, 10:36 AM EST - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Jan 30, 2025, 2:00 AM EST - 1 year ago

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 3:05 AM EST - 1 year ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

MaxCyte Announces Retirement of Board Member Art Mandell

Dec 23, 2024, 2:00 AM EST - 1 year ago

MaxCyte Announces Retirement of Board Member Art Mandell

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

Dec 9, 2024, 2:00 AM EST - 1 year ago

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Nov 13, 2024, 8:05 AM EST - 1 year ago

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:01 PM EST - 1 year ago

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

Nov 6, 2024, 4:05 PM EST - 1 year ago

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

MaxCyte to Participate in Two Upcoming Investor Conferences

Oct 31, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in Two Upcoming Investor Conferences

MaxCyte Appoints Cynthia Collins to its Board of Directors

Oct 15, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 11, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

Oct 10, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

Oct 4, 2024, 5:19 PM EDT - 1 year ago

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

Sep 16, 2024, 2:00 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

Sep 5, 2024, 4:05 PM EDT - 1 year ago

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 12:09 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

Aug 6, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 9, 2024, 4:05 PM EDT - 1 year ago

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

May 29, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

May 22, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript

May 11, 2024, 8:35 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

May 7, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 10, 2024, 8:05 AM EDT - 2 years ago

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Apr 2, 2024, 8:05 AM EDT - 2 years ago

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 10:40 PM EDT - 2 years ago

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

Mindegap
Mindegap Mar. 6 at 7:57 PM
$MXCT My understanding is that $PRME works with their tech and they are planning to file a BLA for their ex vivo CGD following final FDA alignment. If approved will be the first prime editing drug on the market. DYODD, not financial advice.
1 · Reply
BeefStewart
BeefStewart Mar. 5 at 9:19 PM
$MXCT not bad today. 🙏
0 · Reply
BeefStewart
BeefStewart Mar. 5 at 5:42 PM
$MXCT 🙏🩵
0 · Reply
Mindegap
Mindegap Mar. 5 at 4:41 PM
$MXCT Interesting and odd... But no complaints!
1 · Reply
Playtheplayers
Playtheplayers Mar. 4 at 4:58 PM
$MXCT I sold glta
0 · Reply
BeefStewart
BeefStewart Mar. 2 at 9:01 PM
$MXCT what a day.
0 · Reply
BeefStewart
BeefStewart Mar. 2 at 8:04 PM
$CRSP $MXCT seems to be showing signs of life too!
0 · Reply
BeefStewart
BeefStewart Mar. 2 at 1:01 PM
$MXCT $QURE and $CLPT dropping... $NTLA up... Wondering if/how MaxCyte will react to these premarket updates...
0 · Reply
BeefStewart
BeefStewart Feb. 27 at 9:28 PM
$MXCT Not bad.
0 · Reply
CH_Expat
CH_Expat Feb. 27 at 5:12 PM
$MXCT Only 35% down.
1 · Reply
BeefStewart
BeefStewart Feb. 26 at 3:57 PM
$CRSP $PRME $NTLA $MXCT 🥹❤️❤️🙏🙏
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 25 at 7:37 PM
$MXCT Current Stock Price: $0.79 Contracts to trade: $2.5 MXCT Apr 17 2026 Call Entry: $0.05 Exit: $0.07 ROI: 53% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Mindegap
Mindegap Feb. 25 at 3:41 PM
$MXCT This is an actual, working company that makes the picks and shovels for non-viral ex-vivo cell engineering. Super important because the field is actively shifting from viral to non-viral!
1 · Reply
BeefStewart
BeefStewart Feb. 25 at 3:36 PM
$MXCT
3 · Reply
Mindegap
Mindegap Feb. 25 at 3:35 PM
$MXCT Who uses their tech? 9 of the top 10 global biopharmas. Plus: CRSP ALLO CRBU BEAM PRME EDIT SANA NKTX (now private) TGTX ADCE LEGN Research institutes like NIH, academic labs.
0 · Reply
Jptrader3
Jptrader3 Feb. 25 at 2:37 PM
$MXCT Watching
0 · Reply
Mindegap
Mindegap Feb. 24 at 8:57 PM
$CRBU, $PRME, $MXCT, $ABSI Finally.
1 · Reply
BeefStewart
BeefStewart Feb. 24 at 8:24 PM
$MXCT 👀
0 · Reply
BeefStewart
BeefStewart Feb. 24 at 3:14 PM
$MXCT $XBI $CRSP $VRTX https://finance.yahoo.com/news/maxcyte-unveils-expert-dtx-96-130500042.html I think today's press release is very bullish and further validates the importance of ex vivo technology. Especially given the timing of it, as $GILD announced that it acquired Arcellx yesterday for their ex-vivo treatment.
0 · Reply
BeefStewart
BeefStewart Feb. 24 at 2:59 PM
$MXCT https://finance.yahoo.com/news/maxcyte-unveils-expert-dtx-96-130500042.html
0 · Reply
BeefStewart
BeefStewart Feb. 24 at 2:58 PM
$MXCT
0 · Reply
BeefStewart
BeefStewart Feb. 24 at 2:43 PM
$MXCT https://www.stocktitan.net/news/MXCT/max-cyte-unveils-ex-pert-d-tx-tm-a-96-well-electroporation-platform-q58aab4iix14.html
0 · Reply